Looking at the diary, today is the most important day of the week. The Bank of England and the Swiss National Bank meet. The UK reports retail sales. EMU reports CPI figures. The US reports retail sales, industrial output, and two September Fed surveys. Yet the economic updates are unlikely change sentiment ahead of next week FOMC and BOJ meetings.
The euro has been confined to a $1.1200-$1.1285 range since the end of last week. It is in the middle of the that range as the European session gets underway. The dollar peaked yesterday near JPY103.35 and is a big figure lower. It been capped near JPY102.50 in Asia. Support is seen near JPY101.80. Sterling is flat, though Asia initially took it through yesterday’s high before peaking near $1.3280. Technically, there appears to be potential toward $1.3300-$1.3330. The dollar-bloc is little changed, with the US dollar trading near seven-week highs against the Canadian and Australian dollars.
Best Canadian Stocks To Watch Right Now: Talisman Energy Inc.(TLM)
- [By Jayson Derrick]
On the other hand, the analysts are Underweight on Eni SpA (ADR) (NYSE: E), Repsol Oil & Gas Canada Inc (USA) (NYSE: TLM) and OMV AG given their asset bases, which offer an inferior risk to reward profile and limited differentiation in cost reductions.
Best Canadian Stocks To Watch Right Now: Nu Skin Enterprises Inc.(NUS)
- [By Ben Levisohn]
Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:
“Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…
Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.
Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.
Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.
- [By Scott Rubin]
Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.
- [By Roberto Pedone]
Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.
Monday’s Volume: 2 million
Three-Month Average Volume: 900,802
Volume % Change: 85%
From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.
Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.
- [By Craig Jones]
Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.
Best Canadian Stocks To Watch Right Now: Safeway Inc.(SWY)
- [By Peter Graham]
A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:
- [By Peter Graham]
A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:
Best Canadian Stocks To Watch Right Now: Valeant Pharmaceuticals International Inc(VRX)
- [By Paul Ausick]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2.4% Monday to post a new 52-week low of $8.31 after closing Friday at $8.51. The stock’s 52-week high is $38.50. Volume of around 13.5 million shares was about 65% below the daily average of around 18.8 million. The company had no specific news, and shares are on track to add about 1.5% by the closing bell.
- [By Chris Lange]
Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares had an incredible gain on Tuesday after the company announced a licensing agreement with Valeant Pharmaceuticals International Inc. (NYSE: VRX). At one point in the day shares were up over 100%. According to the deal, Eyegate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the Eyegate II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
- [By Kumar Abhishek]
Source:Micron Technology Inc Technical Charts by amigobulls.com
Valeant Pharmaceuticals Intl Inc (NASDAQ:VRX) stock facing resistance.
Shares of specialty pharma company Valeant Pharmaceuticals Intl Inc (NYSE:VRX)are in a downtrend for more than two months now. Valeant Pharmaceuticals Intl Inc stock was down by almost 50% since its Q1 2017 earnings at the end of February. The stock had made a new 52-week low at $8.36 a week back. Since then the stock has been able to make a marginal recovery, gaining more than 10% this week. However, the stock is now facing resistance from its 20-day moving average. Valeant stock had been unable to break out above the resistance line in the past and had continued to slide downwards. The stock is again likely to face strong resistance from the 20-day moving average. The declining volumes over the week indicate that the stock will find it tough to make a bullish crossover, over the 20-day moving average.
- [By Ben Levisohn]
If it feels like it’s been all Valeant Pharmaceuticals International (VRX) today, I get it, and I promise this will be my last post on the company today. But really, how often do we get to see a fund manager acknowledge a spectacular mistake in such publicfashion?
Photo: Andrew Harrer/Bloomberg
As if it weren’t obvious yet, Ackman’s exit is bad news for the stock.Yes, some analysts have tried to focus on other issues that could be positive, but, really, as long as Ackman was around, you knew someone big had Valeant’s back. And now he’s gone. We at Barron’s were never too enthusiastic about Valeant–Vito Racanelliwrote bearishly on the company 2014–or Ackman’s involvement. But it he was your reason to be in Valeant, well consider what Wells Fargo analyst David Maris has to say:
…we believe investors will take Pershing Squares exit as a reflection that 1) the outlook is negative; 2) the potential for meaningful near-term asset sales is unlikely; 3) the legal proceedings/investigations may have greater risk than the Street is appreciating; 4) a turnaround will take longer than expected or is not possible; and 5) the debtholders have an advantaged position in the capital structure, and as such the equity holders are at their mercy, especially in a bankruptcy situation. We believe investors would consider this as a sign that the next several years may not represent a major turnaround for the company.
Shares of Valeant have dropped 11% to$10.76 at 3:12 p.m.
- [By Lisa Levin]
Tiffany & Co. (NYSE: TIF) reported upbeat earnings for its fourth quarter on Friday.
Adobe Systems Incorporated (NASDAQ: ADBE) reported better-than-expected results for its first quarter and issued a strong forecast for the current quarter.
Tesla Inc (NASDAQ: TSLA) disclosed that it has priced its 1.34 million share common stock offering at $262 per share.
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) disclosed the purchase of 3 million shares by ValueAct — 500,000 shares of March 14, 2017 at $10.88 and the remaining 2.5 million shares at $10.81 per share.